Clinical Study
Grade 2 Spondylolisthesis at L4-5 Treated by XLIF: Safety and Midterm Results in the “Worst Case Scenario”
Table 2
Treatment characteristics.
| | Characteristic | Statistic () |
| | Number of levels treated (average per patient) | 80 (1.3) | | L2-L3 (% of patients) | 2 (3.2) | | L3-L4 (% of patients) | 15 (23.8) | | L4-L5 (% of patients) | 61 (96.8) | | L5-S1 (AxiaLIF) (% of patients) | 2 (3.2) | | Number of GII spondy levels (average per patient) | 63 (1.0) | | Number of total levels treated per case | | | One | 49 (77.8) | | Two | 11 (17.5) | | Three | 3 (4.8) | | Graft material | | | Beta-TCP/HA (%) | 6 (9.5) | | DBM + allograft (%) | 6 (9.5) | | DBM + CCC (%) | 49 (77.8) | | Allograft cellular bone matrix (%) | 2 (3.2) | | Supplemental fixation (GII levels) | | | Unilateral pedicle screws (%) | 53 (84.1) | | Bilateral pedicle screws (%) | 9 (14.3) | | Total pedicle screw fixations (%) | 62 (98.4) | | Transpedicular facet fixation (%) | 1 (1.6) | | Internally fixated implant (%) | 10 (15.9) | | No supplemental fixation (stand alone) (%) | 0 (0) | | Mean hemoglobin change from pre- to postoperative (g) (range) | −1.4 (−3.8–0.5) | | Mean length of hospital stay (days) (range) | 1.21 (0–4) |
|
|
